What does DataMeds AI do?
DataMeds AI, Inc. is the current corporate name of the company formerly known as Wellgistics Health, Inc. Its common stock began trading on the Nasdaq Capital Market under the symbol MEDS on July 22, 2026, replacing WGRX, after the official name and symbol change. The operating model combines pharmaceutical distribution, a licensed pharmacy, prescription-routing and hub technology, third-party logistics, and an emerging health-data strategy.
How the pieces fit together
The legacy distribution operation sells pharmaceutical products to independent retail pharmacies and provides warehousing, pick-pack-ship, inventory management, and other logistics services to manufacturers. Wellgistics Pharmacy dispenses prescriptions and over-the-counter products. DelivMeds and the EinsteinRx hub are intended to route prescriptions, coordinate eligibility and benefits verification, support prior authorization and adherence workflows, and connect providers, patients, pharmacies, payors, and manufacturers. The official corporate website presents these activities as one prescription-access ecosystem.
How does DataMeds AI make money?
The company’s audited statements currently show three realized revenue streams: product distribution, pharmacy retail sales, and third-party logistics. The broader plan adds care-management fees, transaction or SaaS-style platform fees, manufacturer-funded patient-support services, and possible monetization of verified healthcare data. Those technology revenues remain less mature than the physical-product businesses and should be treated as strategic options rather than established earnings engines.
| Revenue engine | Customer | How revenue is recognized | Economic characteristic |
|---|---|---|---|
| Distribution services | Independent pharmacies and manufacturers | Product revenue when goods are delivered | Working-capital intensive; margin depends on purchasing scale and inventory discipline |
| Pharmacy retail | Patients and third-party payors | Prescription revenue when the prescription is delivered | Higher gross-margin potential than wholesale, but exposed to reimbursement and PBM terms |
| Third-party logistics | Small and mid-sized manufacturers | Fees for warehousing and fulfillment services | Service revenue that can leverage existing warehouse infrastructure |
| Hub, data, and clinical services | Manufacturers, providers, payors, and channel partners | Planned transaction, SaaS, care-coordination, and data-related fees | Potentially recurring and less inventory-heavy, but commercialization is still developing |
Which revenue stream mattered most in Q1 2026?
The intended manufacturer-to-patient flow
Which turning points created today’s company?
-
2011–2013Wellgistics Pharmacy and Wellgistics LLC were founded. These operating businesses created the dispensing, wholesaling, and logistics base that still produces reported revenue.
-
2017–2020DelivMeds was formed and later recommissioned as a prescription-transfer and clinical-concierge hub serving independent pharmacies.
-
2022The public-company predecessor was organized and incorporated as Danam Health, establishing the holding-company structure used for acquisitions.
-
2024The Wood Sage and Wellgistics acquisitions closed, adding the pharmacy, technology, distribution, and logistics operations. The company adopted the Wellgistics Health name in October.
-
February 2025The company completed an IPO of 888,889 shares at $4.50 per share and began trading as WGRX, giving it public equity access but also public-company costs and dilution risk.
-
November 2025A license agreement with Datavault AI introduced the PharmacyChain blockchain and smart-contract narrative into the operating strategy.
-
April–May 2026The KareRx joint venture expanded telepharmacy and hub capabilities; management also outlined DelivMeds AI, Tollo Health, and verification-related initiatives in its May 2026 strategy letter.
-
May–July 2026A 1-for-50 reverse split reduced approximately 125.7 million shares to about 2.5 million, followed by the DataMeds AI name and MEDS ticker change.
What does the latest quarter show?
The Form 10-Q for the quarter ended March 31, 2026 shows a business in transition rather than a simple growth story. Consolidated revenue fell sharply because liquidity constraints limited distribution purchasing and order fulfillment. At the same time, pharmacy retail sales expanded and lifted the gross-margin percentage.
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Net revenue | $1.560M | $10.863M | Distribution volume collapsed because the company lacked purchasing liquidity. |
| Gross profit | $0.170M | $0.693M | Absolute gross profit fell, even though mix improved. |
| Gross margin | 10.9% | 6.4% | Higher-margin pharmacy sales became a larger share of revenue. |
| Operating expenses | $6.186M | $32.041M | The decline mainly reflects the absence of a large prior-year stock-compensation charge. |
| Interest expense | $2.073M | $1.094M | Financing costs remained substantial relative to revenue. |
| Operating cash flow | $(3.413)M | $(1.347)M | Cash consumption worsened despite the lower accounting loss. |
Why did the loss improve without cash flow improving?
The Q1 2025 comparison included about $27.8 million of stock-based compensation, while Q1 2026 stock-based compensation was about $1.4 million. That accounting change reduced the reported net loss from $32.4 million to $7.7 million, but it did not solve the operating funding gap. Q1 2026 also included $1.5 million of debt-discount amortization, and accounts payable rose by $1.5 million, indicating that working-capital support came partly from suppliers.
Why did pharmacy replace distribution as the main revenue engine?
| Revenue category | FY2025 | FY2025 mix | Q1 2026 | Q1 2026 mix |
|---|---|---|---|---|
| Distribution | $21.869M | 93.7% | $0.226M | 14.5% |
| Pharmacy retail | $0.866M | 3.7% | $1.134M | 72.7% |
| Third-party logistics | $0.603M | 2.6% | $0.199M | 12.8% |
What does the mix shift mean strategically?
A pharmacy-led model may produce better percentage margins and create direct patient relationships that support adherence and data services. However, the company still needs distribution purchasing power and manufacturer access to make the integrated model work. The strategic task is not simply to abandon wholesale; it is to restore economically disciplined distribution while scaling pharmacy and hub services that require less inventory per dollar of revenue.
How financially strong is DataMeds AI?
The balance sheet is the company’s most immediate constraint. At March 31, 2026, cash was only $51,730, current assets were $2.762 million, and current liabilities were $32.199 million. The resulting $29.437 million working-capital deficit, accumulated deficit of $118.774 million, and negative stockholders’ equity of $15.062 million led the company to repeat a substantial-doubt going-concern warning.
| Balance-sheet item | March 31, 2026 | Why it matters |
|---|---|---|
| Accounts payable | $11.977M | Supplier credit is large relative to current assets and revenue. |
| Convertible notes, current | $6.568M | Creates repayment, conversion, and dilution exposure. |
| Other current debt obligations | $8.604M | Adds near-term refinancing pressure. |
| Long-term notes payable | $12.600M | Limits financial flexibility and raises the hurdle for positive equity value. |
| Goodwill and other intangibles | $24.180M | A large share of assets depends on expected acquisition and technology value. |
How is the company funding operations?
Financing, not operations, kept cash roughly stable in Q1. The company later announced a $21 million convertible-debt refinancing that refinanced prior convertible debt and provided $6.5 million of new capital. That improved near-term funding but introduced additional conversion and dilution complexity. For a financial-health assessment, the decisive metric is whether gross profit and operating cash flow begin to fund the platform before new securities are required again.
What gives DataMeds AI a competitive position?
The company’s strongest potential advantage is integration: manufacturer relationships, a wholesale operation, an affiliated pharmacy, a 6,500-plus pharmacy network, prescription routing, telepharmacy capability, and emerging data tools in one architecture. The KareRx joint venture added an estimated reach of more than 200,000 patient lives and linked provider, pharmacy, and fulfillment workflows.
Is the network already a durable moat?
Not yet. The network can create workflow data, distribution reach, and cross-selling opportunities, but a moat requires high retention, proven economics, reliable service levels, and differentiated technology. The company’s own filings note that many technology licenses are non-exclusive and that larger competitors have more capital, purchasing power, and access to similar drugs. The more accurate description is an emerging strategic position with potentially valuable assets, not a proven barrier to entry.
| Competitive arena | Rivals identified in filings | DataMeds AI’s intended differentiation | Constraint |
|---|---|---|---|
| Digital pharmacy and telehealth | Hims, Amazon/PillPack, Truepill, Capsule, Alto, Roman, Lemonaid | Independent-pharmacy routing plus direct fulfillment and hub support | Competitors have larger consumer brands and funding |
| Specialty-lite hub services | PBMs, specialty pharmacies, provider systems, infusion companies | One workflow spanning eligibility, prior authorization, dispensing, and adherence | Manufacturer adoption and reimbursement access are not guaranteed |
| Wholesale and logistics | National, regional, and niche distributors | Focus on independent pharmacies, smaller manufacturers, and specialized products | Scale disadvantage and high working-capital needs |
| Healthcare data infrastructure | Point solutions and broader healthcare IT platforms | Pharmacy-originated, verified workflow data tied to dispensing events | Commercial model, privacy compliance, and integration remain to be demonstrated |
Who owns the company, and how does governance affect the story?
DataMeds AI has one class of common stock with one vote per share, but ownership has been concentrated among founders, acquisition sellers, executives, trusts, and related entities. The latest detailed beneficial-ownership table was included in the company’s fiscal 2025 Form 10-K and used a March 2, 2026 pre-reverse-split share count.
| Holder or group | Beneficial shares | Economic stake | Governance relevance |
|---|---|---|---|
| Brian Norton, former CEO | 18,204,807 | 17.20% | Includes interests through Strategix Global and Nomad Capital tied to the Wellgistics acquisition. |
| Suren Ajjarapu | 12,826,558 | 12.12% | Meaningful founder-related influence through direct and affiliated holdings. |
| Prashant Patel | 10,990,247 | 10.38% | Management ownership aligns incentives but also concentrates voting influence. |
| Annapurna Gundlapalli Revocable Trust | 8,944,000 | 8.45% | A separate large-holder block disclosed in the filing. |
| Directors and executive officers as a group | 41,182,021 | 41.66% | High insider influence over strategic and capital-structure decisions. |
What changed after the reverse split?
The 1-for-50 reverse split effective May 26, 2026 reduced approximately 125,671,251 outstanding shares to about 2,513,425. It did not change proportional ownership by itself, but it highlights the company’s dependence on continued Nasdaq compliance and makes future conversions, warrants, preferred stock, and equity awards important to model on a fully diluted basis.
What opportunities and risks could change the outlook?
Which operating milestones could create value?
Which risks are most material?
| Risk | Financial transmission | Metric or event to monitor |
|---|---|---|
| Liquidity and going concern | Inventory shortages, delayed shipments, expensive financing, or reduced development scope | Cash, operating cash burn, working-capital deficit, new financing terms |
| Dilution and conversion | Existing holders’ economic interest can shrink as debt, warrants, and preferred securities convert | Fully diluted shares and conversion prices after the reverse split |
| PBM and reimbursement exposure | Network exclusions, reimbursement changes, and DIR-type fees can reduce pharmacy revenue and margin | Prescription volume, reimbursement per script, gross margin |
| Technology and data compliance | HIPAA, privacy, cybersecurity, AI, and smart-contract failures could delay adoption or create liability | Commercial launches, audits, incidents, and regulatory disclosures |
| Acquisition and partnership execution | Announced transactions may not close, integrate, or generate expected revenue | Definitive closings, purchase consideration, integration costs, segment disclosure |
| Competitive scale | Larger distributors, PBMs, pharmacies, and digital-health firms can outspend or underprice the company | Customer retention, product availability, pricing, and network growth |
Which KPIs matter most for valuation?
What should a researcher model explicitly?
Why annual context still matters
Fiscal 2025 revenue increased 28.7% from $18.1 million to $23.3 million, but cost of revenue reached $29.8 million and produced a $6.4 million gross loss. The company attributed the deterioration to liquidity constraints and an approximately $6.0 million aged-inventory reserve. Operating cash outflow was $10.9 million, while financing cash inflow was $10.8 million. The annual pattern and Q1 2026 pattern tell the same story: business development is being financed externally, and valuation depends on converting that investment into self-funded gross profit.
What is the key takeaway from DataMeds AI analysis?
The financial evidence is much less mature than the strategic narrative. Q1 2026 showed pharmacy growth and a higher gross-margin percentage, but consolidated revenue fell 85.6%, operating cash outflow reached $3.4 million, cash remained near $0.05 million, and the company carried a $29.4 million working-capital deficit. The May 2026 refinancing supplied capital, yet future conversions and preferred securities can materially reshape ownership.
What should students and investors monitor next?
- Whether pharmacy revenue continues to scale after the April 2026 preliminary monthly level.
- Whether distribution revenue recovers with positive gross profit rather than inventory write-downs.
- Whether KareRx patient access becomes active prescriptions and reported service revenue.
- Whether EinsteinRx and PharmacyChain produce separately identifiable recurring revenue.
- Whether gross profit grows faster than cash operating expenses and interest burden.
- Whether the company reduces operating cash burn before needing another financing round.
- How the post-split fully diluted share count changes after debt, warrants, and preferred securities.
- Whether leadership stability and regulatory execution improve as the DataMeds AI strategy expands.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.